Redeye retains its positive view of Lime following the Q4 report. While ARR growth and EBITDA-CAPEX was somewhat lower than anticipated, we have a hard time finding fundamental reasons for the 22% share price decline. We have been positive for a while, and we have been wrong, yet we believe the long-term risk/reward is appealing at 12.8x EBITDA-CAPEX 2026e.
LÄS MER
